{"id":"csf-1-component-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CSF-1 Component #1 works by binding to the colony-stimulating factor 1 receptor, which is involved in the regulation of immune cells. This interaction can modulate the activity of these cells, potentially leading to therapeutic effects. However, the exact mechanism of action is not fully understood.","oneSentence":"CSF-1 Component #1 is a protein that modulates the activity of the colony-stimulating factor 1 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:09:16.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of age-related macular degeneration"}]},"trialDetails":[{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT02584647","phase":"PHASE1, PHASE2","title":"PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors","status":"TERMINATED","sponsor":"Gulam Manji","startDate":"2015-11-04","conditions":"Sarcoma, Malignant Peripheral Nerve Sheath Tumors","enrollment":39},{"nctId":"NCT02728102","phase":"PHASE2","title":"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2016-07","conditions":"Multiple Myeloma","enrollment":203},{"nctId":"NCT03885011","phase":"PHASE2","title":"A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"Orasis Pharmaceuticals Ltd.","startDate":"2019-02-26","conditions":"Presbyopia","enrollment":166},{"nctId":"NCT01045460","phase":"PHASE2","title":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-01-15","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT01174082","phase":"PHASE2","title":"Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-20","conditions":"Myeloma","enrollment":2},{"nctId":"NCT00791037","phase":"PHASE1, PHASE2","title":"Vaccine Therapy in Treating Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2008-10","conditions":"HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer","enrollment":23},{"nctId":"NCT00613509","phase":"PHASE2","title":"Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Melanoma, Cancer","enrollment":23},{"nctId":"NCT00499343","phase":"PHASE2","title":"G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01","conditions":"Lymphoma","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CSF-1 Component #1","genericName":"CSF-1 Component #1","companyName":"Orasis Pharmaceuticals Ltd.","companyId":"orasis-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CSF-1 Component #1 is a protein that modulates the activity of the colony-stimulating factor 1 receptor. Used for Treatment of age-related macular degeneration.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}